Authors' objectives: Graft vs host disease (GvHD) can occur after a bone marrow or stem cell transplant; it happens when particular types of white blood cell in the donated bone marrow or stem cells attack your own body cells. GvHD can be unpleasant and in some cases life threatening. Symptoms include painful rashes and being sick. Remestemcel-L is a new drug given in a drip (directly into a vein). Some studies have suggested remestemcel-L may be helpful for people whose first treatment for GvHD has failed, which is a very serious situation. More studies are now aiming to show how well it works and that it is safe to use. If remestemcel-L is licenced for use in the UK, it could be a new treatment option for children with severe GvHD when current treatments have stopped working.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/remestemcel-l-for-graft-vs-host-disease-in-paediatric-patients-second-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)